Cardiovascular Disease Assessment Prior to Kidney Transplantation

Area of Science:

• Nephrology
• Cardiology
• Transplantation Medicine

Background:

• Cardiovascular disease (CVD) is a major cause of mortality in patients with chronic kidney disease (CKD), end-stage kidney disease (ESKD), and kidney transplant recipients.
• Kidney transplantation improves survival and quality of life, reducing CVD events, making it the optimal treatment for advanced kidney disease.
• Pretransplantation cardiovascular assessment aims to detect asymptomatic cardiac disease to enhance patient and allograft survival.

Purpose of the Study:

• To review current clinical practice guidelines for pretransplantation cardiovascular assessment.
• To discuss recent study findings regarding screening de-escalation and preemptive revascularization.
• To evaluate future directions for cardiovascular disease assessment in kidney transplant candidates.

Main Methods:

• Summary of current clinical practice guidelines based on expert opinion.
• Analysis of recent studies on cardiovascular screening in kidney transplant candidates.
• Discussion of optimal medical therapy and its role in managing CVD risk.

Main Results:

• Current guidelines for cardiovascular assessment lack high-quality evidence and standardized practices.
• Recent studies suggest de-escalation of screening and avoidance of preemptive revascularization in asymptomatic patients.
• Clear guidance on assessing cardiovascular fitness in this high-risk population is still needed.

Conclusions:

• Kidney transplantation is the optimal treatment for advanced kidney disease, but CVD remains a significant concern.
• Standardized, evidence-based guidelines are needed for pretransplantation cardiovascular assessment.
• Further research is required to optimize CVD risk stratification and management in kidney transplant candidates.